Pneumococcal Vaccines in Patients With Asthma
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.
Full description
Patients will be randomized into either PCV13 and PPSV23 (Experimental) or PPSV23 alone (Active comparator). At the Week 0 time point, the patients will receive either PCV13 (Experimental) or PPSV23 (Active comparator) and undergo a blood draw of 5ml for assessment of pre-vacation serotype titers. The Active Comparator group will undergo a 5ml draw of blood for assessment of titers at week 8, 16, and 24 following vaccination. The Experimental group will undergo vaccination with PPSV23 at week 8 with 5 ml blood draw for pneumococcal serotype titers as well as a blood draw at week 16 and week 24.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosis of asthma
Exclusion criteria
- Research exemption requested
- History of PCV-13 vaccination
- History of cochlear implant
- Cerebrospinal Fluid (CSF) leak
- Congestive Heart Failure (CHF)
- Diabetes Mellitus (DM)
- Chronic Kidney Disease (CKD)
- Human Immunodeficiency Virus (HIV)
- Common Variable Immune Deficiency (CVID)
- Patients who have received the PPSV23 vaccine in the last 5 years
- Women who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations)
Trial design
Primary purpose
Allocation
Interventional model
Masking
17 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal